Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine in treating patients who have relapsed primary acute myelogenous leukemia.

Key facts

Study ID

NCT00017342

Run by

Virginia Commonwealth University

Starts

2001-07-01

Expected to finish

2005-06-01

Last updated by the study team

2010-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Massey Cancer Center at Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.